DeepMed Research

Supernus Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2005-01-01

Employees: 652

Market Cap: $1.9B

Website: http://www.supernus.com

Introduction: Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.

Clinical Trials

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures

Phase 2

Recruiting

Conditions: Focal Onset Seizures

Interventions: Drug: SPN-817
Drug: Placebo

First Posted Date: 2025-01-29

Last Posted Date: 2025-02-06

Lead Sponsor: Supernus Pharmaceuticals, Inc.

Target Recruit Count: 258

Registration Number: NCT06798896

Locations: 🇺🇸
Medsol Clinical Research Center, Port Charlotte, Florida, United States

Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women

Phase 4

Completed

Conditions: Healthy Lactating Women

Interventions: Drug: SPN-812 (600mg, QD)

First Posted Date: 2024-02-14

Last Posted Date: 2024-06-06

Lead Sponsor: Supernus Pharmaceuticals, Inc.

Target Recruit Count: 15

Registration Number: NCT06259331

Locations: 🇺🇸
PPD Phase I Clinic, Las Vegas, Nevada, United States

Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms

Phase 4

Active, not recruiting

Conditions: Attention-Deficit/Hyperactivity Disorder

Interventions: Drug: SPN-812

First Posted Date: 2023-12-29

Last Posted Date: 2025-01-13

Lead Sponsor: Supernus Pharmaceuticals, Inc.

Target Recruit Count: 750

Registration Number: NCT06185985

Locations: 🇺🇸
ObvioHealth, New York, New York, United States

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

Phase 2

Recruiting

Conditions: Epilepsy
Seizures, Epileptic

Interventions: Drug: SPN-817

First Posted Date: 2022-08-26

Last Posted Date: 2023-03-20

Lead Sponsor: Supernus Pharmaceuticals, Inc.

Target Recruit Count: 35

Registration Number: NCT05518578

Locations: 🇦🇺
Alfred Hospital, Melbourne, Australia

Mass Balance Study of NV-5138 in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: [14C]-NV-5138

First Posted Date: 2022-05-23

Last Posted Date: 2022-05-23

Lead Sponsor: Supernus Pharmaceuticals, Inc.

Target Recruit Count: 6

Registration Number: NCT05384977

Locations: 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom

Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects

Early Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: SPN-817, Treatment B
Drug: SPN-817, Treatment C
Drug: BIS-001, Treatment A

First Posted Date: 2021-11-01

Last Posted Date: 2022-08-30

Lead Sponsor: Supernus Pharmaceuticals, Inc.

Target Recruit Count: 30

Registration Number: NCT05102552

Locations: 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia

Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Pediatric Subjects

Phase 3

Not yet recruiting

Conditions: Sialorrhea

Interventions: Drug: MYOBLOC Low Dose
Drug: MYOBLOC High Dose
Drug: Placebo

First Posted Date: 2021-10-27

Last Posted Date: 2022-12-19

Lead Sponsor: Supernus Pharmaceuticals, Inc.

Target Recruit Count: 108

Registration Number: NCT05097079

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity

Phase 2

Active, not recruiting

Conditions: Spasticity
Cervical Spinal Cord Injury
Cerebral Palsy
Cerebrovascular Accident
Multiple Sclerosis
Traumatic Brain Injury

Interventions: Drug: Phase 3; Placebo
Drug: Phase 2; Low Dose MYOBLOC
Drug: Phase 2; High Dose MYOBLOC
Drug: Phase 2; Placebo
Drug: Phase 3; MYOBLOC

First Posted Date: 2021-03-25

Last Posted Date: 2023-03-07

Lead Sponsor: Supernus Pharmaceuticals, Inc.

Target Recruit Count: 272

Registration Number: NCT04815967

Locations: 🇨🇿
Centrum pro intervenční terapii motorických poruch, Neurologická klinika, Univerzita Karlova Katerinska, Prague, Czechia
🇺🇸
Rancho Research Institute, Downey, California, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 6 locations

Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD

Phase 4

Completed

Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD)

Interventions: Drug: SPN-812

First Posted Date: 2021-03-08

Last Posted Date: 2024-05-01

Lead Sponsor: Supernus Pharmaceuticals, Inc.

Target Recruit Count: 96

Registration Number: NCT04786990

Locations: 🇺🇸
Psychiatric Associates Purehealth Medical Center, Overland Park, Kansas, United States
🇺🇸
SP Research, PLLC, Oklahoma City, Oklahoma, United States
🇺🇸
Elite Clinical Trials, Rexburg, Idaho, United States

and more 13 locations

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

Phase 4

Recruiting

Conditions: Attention-Deficit/Hyperactivity Disorder

Interventions: Drug: Placebo
Drug: 100mg SPN-812

First Posted Date: 2021-03-04

Last Posted Date: 2025-05-07

Lead Sponsor: Supernus Pharmaceuticals, Inc.

Target Recruit Count: 286

Registration Number: NCT04781140

Locations: 🇺🇸
Med Clinical Research, Irvington, New Jersey, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
AIM Trials, Plano, Texas, United States

and more 41 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy